These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 31253571)

  • 1. Anti-KIR3DL2 therapy in the treatment of Sézary syndrome.
    Quaglino P
    Lancet Oncol; 2019 Aug; 20(8):1048-1049. PubMed ID: 31253571
    [No Abstract]   [Full Text] [Related]  

  • 2. KIR3DL2 in cutaneous T-cell lymphoma: from a promising biomarker to a potential therapeutic target.
    Sun J; Wang Y
    Br J Dermatol; 2020 Jun; 182(6):1325-1326. PubMed ID: 31808144
    [No Abstract]   [Full Text] [Related]  

  • 3. KIR3DL2 expression in cutaneous T-cell lymphomas: expanding the spectrum for KIR3DL2 targeting.
    Battistella M; Leboeuf C; Ram-Wolff C; Hurabielle C; Bonnafous C; Sicard H; Bensussan A; Bagot M; Janin A
    Blood; 2017 Dec; 130(26):2900-2902. PubMed ID: 29089310
    [No Abstract]   [Full Text] [Related]  

  • 4. IPH4102, a monoclonal antibody directed against the immune receptor molecule KIR3DL2, for the treatment of cutaneous T-cell lymphoma.
    Van Der Weyden C; Bagot M; Neeson P; Darcy PK; Prince HM
    Expert Opin Investig Drugs; 2018 Aug; 27(8):691-697. PubMed ID: 30001170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Epidermotropic T cell lymphomas as models for tumor progression].
    Bagot M; Bensussan A
    Med Sci (Paris); 2006 Feb; 22(2):192-6. PubMed ID: 16457762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KIR3DL2/CpG ODN interaction mediates Sézary syndrome malignant T cell apoptosis.
    Ghazi B; Thonnart N; Bagot M; Bensussan A; Marie-Cardine A
    J Invest Dermatol; 2015 Jan; 135(1):229-237. PubMed ID: 25007046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Usefulness of KIR3DL2 to Diagnose, Follow-Up, and Manage the Treatment of Patients with Sézary Syndrome.
    Hurabielle C; Thonnart N; Ram-Wolff C; Sicard H; Bensussan A; Bagot M; Marie-Cardine A
    Clin Cancer Res; 2017 Jul; 23(14):3619-3627. PubMed ID: 28119365
    [No Abstract]   [Full Text] [Related]  

  • 8. Single-cell RNA-sequencing reveals predictive features of response to pembrolizumab in Sézary syndrome.
    Su T; Duran GE; Kwang AC; Ramchurren N; Fling SP; Kim YH; Khodadoust MS
    Oncoimmunology; 2022; 11(1):2115197. PubMed ID: 36046812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD158k/KIR3DL2 is a new phenotypic marker of Sezary cells: relevance for the diagnosis and follow-up of Sezary syndrome.
    Poszepczynska-Guigné E; Schiavon V; D'Incan M; Echchakir H; Musette P; Ortonne N; Boumsell L; Moretta A; Bensussan A; Bagot M
    J Invest Dermatol; 2004 Mar; 122(3):820-3. PubMed ID: 15086570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD158K/KIR3DL2 transcript detection in lesional skin of patients with erythroderma is a tool for the diagnosis of Sézary syndrome.
    Ortonne N; Le Gouvello S; Mansour H; Poillet C; Martin N; Delfau-Larue MH; Leroy K; Farcet JP; Bagot M; Bensussan A
    J Invest Dermatol; 2008 Feb; 128(2):465-72. PubMed ID: 17703174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [New developments in Sézary syndrome].
    Caudron A; Marie-Cardine A; Bensussan A; Bagot M
    Ann Dermatol Venereol; 2012 Jan; 139(1):31-40. PubMed ID: 22225740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigative drugs for the treatment of cutaneous T-cell lymphomas (CTCL): an update.
    Ramelyte E; Dummer R; Guenova E
    Expert Opin Investig Drugs; 2019 Sep; 28(9):799-809. PubMed ID: 31398295
    [No Abstract]   [Full Text] [Related]  

  • 13. IPH4102, a humanized KIR3DL2 antibody with potent activity against cutaneous T-cell lymphoma.
    Marie-Cardine A; Viaud N; Thonnart N; Joly R; Chanteux S; Gauthier L; Bonnafous C; Rossi B; Bléry M; Paturel C; Bensussan A; Bagot M; Sicard H
    Cancer Res; 2014 Nov; 74(21):6060-70. PubMed ID: 25361998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The emergence of Sézary cells during the treatment of cutaneous T-cell lymphoma.
    Sato M; Ishikawa O; Miyachi Y
    Br J Dermatol; 1995 Nov; 133(5):810-3. PubMed ID: 8555042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is Sézary syndrome a true primary cutaneous lymphoma?
    Alaibac M; Pigozzi B; Bordignon M
    Int J Dermatol; 2008 Nov; 47(11):1195-6. PubMed ID: 18986460
    [No Abstract]   [Full Text] [Related]  

  • 16. KIR3DL2 (CD158k) is a potential therapeutic target in primary cutaneous anaplastic large-cell lymphoma.
    Battistella M; Janin A; Jean-Louis F; Collomb C; Leboeuf C; Sicard H; Bonnafous C; Dujardin A; Ram-Wolff C; Kadin ME; Bensussan A; Bagot M; Michel L
    Br J Dermatol; 2016 Aug; 175(2):325-33. PubMed ID: 27037558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KIR3DL2 may represent a novel therapeutic target in aggressive systemic peripheral T-cell lymphoma.
    Decroos A; Cheminant M; Bruneau J; Carras S; Parinet V; Pelletier L; Lacroix L; Martin N; Giustiniani J; Lhermitte L; Asnafi V; Battistella M; Lemonnier F; De Leval L; Sicard H; Bonnafous C; Gauthier L; Genestier L; Caruso S; Gaulard P; Hermine O; Ortonne N
    Haematologica; 2023 Oct; 108(10):2830-2836. PubMed ID: 37165836
    [No Abstract]   [Full Text] [Related]  

  • 18. Killer cell immunoglobulin-like receptor expression delineates in situ Sézary syndrome lymphocytes.
    Wechsler J; Bagot M; Nikolova M; Parolini S; Martin-Garcia N; Boumsell L; Moretta A; Bensussan A
    J Pathol; 2003 Jan; 199(1):77-83. PubMed ID: 12474229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of cell surface molecules characterizing human cutaneous T-cell lymphomas.
    Nikolova M; Bagot M; Boumsell L; Bensussan A
    Leuk Lymphoma; 2002 Apr; 43(4):741-6. PubMed ID: 12153159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Folliculotropic Sézary syndrome: a new variant of cutaneous T-cell lymphoma.
    Gerami P; Guitart J
    Br J Dermatol; 2007 Apr; 156(4):781-3. PubMed ID: 17286634
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.